Inventiva Pharma is a biopharmaceutical company focused on the development of innovative oral small molecule therapies for patients with significant unmet medical needs, particularly in the areas of non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses (MPS). The company leverages its expertise in drug discovery and development to create differentiated treatments that address critical gaps in the current therapeutic landscape. Inventiva operates in the global biopharmaceutical market, targeting healthcare providers and patients who require advanced treatment options for complex diseases. The business model is centered around the research and development of proprietary drug candidates, which are then advanced through clinical trials to regulatory approval and commercialization. Revenue is generated through a combination of licensing agreements, partnerships, and eventual product sales. Inventiva's pipeline includes clinical-stage assets such as odiparcil, which has received FDA Fast Track designation for MPS VI, underscoring the company's commitment to accelerating drug discovery and delivering impactful treatments.

Keywords: biopharmaceutical, drug discovery, NASH, MPS, clinical trials, FDA Fast Track, oral therapies, unmet medical needs, odiparcil, innovative treatments.